GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » G Medical Innovations Holdings Ltd (OTCPK:GMVDF) » Definitions » Debt-to-EBITDA

G Medical Innovations Holdings (G Medical Innovations Holdings) Debt-to-EBITDA : -2.58 (As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is G Medical Innovations Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

G Medical Innovations Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $1.81 Mil. G Medical Innovations Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.28 Mil. G Medical Innovations Holdings's annualized EBITDA for the quarter that ended in Dec. 2022 was $-0.81 Mil. G Medical Innovations Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 was -2.58.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for G Medical Innovations Holdings's Debt-to-EBITDA or its related term are showing as below:

GMVDF's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.26
* Ranked among companies with meaningful Debt-to-EBITDA only.

G Medical Innovations Holdings Debt-to-EBITDA Historical Data

The historical data trend for G Medical Innovations Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G Medical Innovations Holdings Debt-to-EBITDA Chart

G Medical Innovations Holdings Annual Data
Trend Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial -0.88 -1.47 -0.34 -0.90 -0.24

G Medical Innovations Holdings Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.47 -0.70 -0.13 -2.58

Competitive Comparison of G Medical Innovations Holdings's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, G Medical Innovations Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


G Medical Innovations Holdings's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, G Medical Innovations Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where G Medical Innovations Holdings's Debt-to-EBITDA falls into.



G Medical Innovations Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

G Medical Innovations Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.809 + 0.283) / -8.652
=-0.24

G Medical Innovations Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.809 + 0.283) / -0.81
=-2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2022) EBITDA data.


G Medical Innovations Holdings  (OTCPK:GMVDF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


G Medical Innovations Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of G Medical Innovations Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


G Medical Innovations Holdings (G Medical Innovations Holdings) Business Description

Traded in Other Exchanges
N/A
Address
5 Oppenheimer Street, Rehovot, ISR, 7670105
G Medical Innovations Holdings Ltd is a mobile health (mHealth), telemedicine solutions, and monitoring service platforms. It develops and markets clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for e-health projects. The company offers a suite of both consumer and clinical grade products and platforms which are positioned to reduce inefficiencies in healthcare delivery, improve access, reduce costs, increase the quality of care, and make healthcare more personalized and precise. Its operating segment includes Products, Patient Services, and Covid-19 testing. The company generates maximum revenue from the Patient Services segment.
Executives
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022

G Medical Innovations Holdings (G Medical Innovations Holdings) Headlines

From GuruFocus